1	Comprehensive evaluation of the use of intravitreal injection of anti-
2	vascular endothelial growth factor drugs in patients with fundus
3	lesions based on real-world data
4	Cheng-qun Chen ^{a1*} , Li-ping Du ^b , Qing Liu ^c , Qing-hua Ren ^a , Zhen-feng
5	Zhu ^a , Gui-fang Sun ^d , Yu-shen Li ^e , Yang Yang ^e , Shu-zhang Du ^a , Yue-
6	dong Qi ^a
7	^a Department of Pharmaceutical Sciences, The First Affiliated Hospital of Zhengzhou
8	University, Zhengzhou, China.
9	^b ophthalmologic, The First Affiliated Hospital of Zhengzhou University, Zhengzhou,
10	China.
11	^c School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, China.
12	^d Department of neurology, The First Affiliated Hospital of Zhengzhou University,
13	Zhengzhou, China.
14	^e Information Department, The First Affiliated Hospital of Zhengzhou University,
15	Zhengzhou, China.
16	

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

17 Abstract

18 The prevalence of fundus lesion-related diseases is increasing, which ophthalmic anti-VEGF drugs have become the drugs of choice for the treatment of fundus lesions 19 20 diseases. To evaluate the clinical value of three ophthalmic anti-VEGF drugs in the 21 treatment of fundus lesions diseases, to guide the rational use of the clinic. Inpatients 22 with fundus lesions who had intravitreal injections of Aflibercept, Conbercept and 23 Leizumab during 2020 were studied and six indicators were selected for a 24 comprehensive evaluation. In terms of safety, Aflibercept, Conbercept, and Leizumab 25experienced adverse effects of elevated Intraocular Pressure (IOP). In terms of 26 effectiveness, Leizumab was strong, that of Aflibercept was stronger and that of 27 Conbercept was weaker. In terms of economic, there was no significant difference in 28 the cost of Aflibercept, Conbercept and Leizumab and a significant difference in the 29 total treatment cost and the cost of surgery. In terms of appropriateness, Aflibercept 30 was more suitable than Conbercept, and there was no significant difference between 31 Leizumab and Aflibercept. In terms of accessibility, Aflibercept, Conbercept and 32 Leizumab were all accessible to urban residents in Henan Province. For rural people, 33 these are unreachable. In terms of innovation, Aflibercep was the most innovative, 34 followed by Leizumab and finally Conbercept. In terms of effectiveness and 35 accessibility, Leizumab performed best compared to Aflibercept and Conbercept. In 36 terms of accessibility and innovation, Aflibercept performed best compared to

37 Conbercept and Leizumab. In terms of safety and economic, Aflibercept, Conbercept
 38 and Leizumab performed comparably.

39

40 Introduction

41 The number of patients with age-related fundus diseases is increasing in China, 42 becoming a major cause of irreversible visual impairment in the middle-aged and 43 elderly population and seriously affecting the lives of patients(1). In the future, this 44 burden will be exacerbated by the ageing of the population(2). With the introduction of 45 anti-angiogenic therapies, significant progress has been made in the treatment of 46 exudative or so-called wet age-related macular degeneration(3). Anti-VEGF drugs are 47 increasingly being used in the clinical treatment of ophthalmologically related diseases, 48 and multiple applications are becoming more common (4). They have also shown clear 49 advantages in clinical application, but the changing dynamics of the medical and 50 economic issues associated with this suggest that significant challenges lie ahead(5). A 51 comprehensive evaluation of the economics as well as efficacy-related aspects of these drugs is therefore becoming increasingly important (6). Different approaches to drug 52 53 therapy also carry a corresponding economic burden for patients, and changes in drug therapy can also lead to changes in the economic burden(7). Drugs in this category are 54 55 currently marketed as Aflibercept(7), Conbercept(8) and Leizumab(9). This study evaluates the combined clinical value of three ophthalmic anti-VEGF agents generated 56

in the treatment of diseases associated with fundus lesions based on real-world data.
The results of this study will help patients and physicians, as well as pharmacists, to
promote the clinical use of these drugs and benefit more patients based on the
corresponding findings.

61 Materials and methods

62 Data collection

The study data were obtained from the electronic medical records of the hospital 63 64 information system starting from 2020, and patients discharged from the First Affiliated 65 Hospital of Zhengzhou University in Zhengzhou City, Henan Province, from January 66 2020 to December 2020 were collected, and the collected patients were followed up 67 from 2021 to 2022. Collection criteria: patients who had received intravitreal injection 68 treatment at the First Affiliated Hospital of Zhengzhou University during 2020. Inclusion criteria: (1) age \geq 18 years; (2) clinical diagnosis of fundus-related disease; 69 70 (3) all used any 1 or more drugs of Aflibercept, Conbercept, and Leizumab for the 71treatment of ophthalmic disease during hospitalization. Exclusion criteria: (1) patients 72 explicitly did not agree to follow-up at the return visit; (2) data that were not part of a 73 real-world study.

The total number of cases of Aflibercept, Conbercept, and Leizumab used by all inpatients in the study time cross-section was obtained, and the total number of cases was determined according to the inclusion and exclusion principles. Information was

collected from the hospital medical record system, including hospitalisation number,
age, gender, number of hospitalisations, primary diagnosis, other diagnoses, date of
admission, date of discharge, economics data, data related to adverse drug reactions,
and information on relevant drugs used to combat adverse reactions.

81 Selection of main evaluation indicators

82 The study was based on the "Guidelines for the Management of Comprehensive 83 Clinical Evaluation of Pharmaceuticals (Trial Version 2021)", and the evaluation 84 indicators were determined according to the characteristics of pharmaceutical 85 applications in the real world. Aflibercept, Conbercept and Leizumab were 86 comprehensively evaluated by six indicators including safety, efficacy, economy, 87 suitability, accessibility and innovation. The accessibility of Aflibercept, Conbercept 88 and Leizumab was evaluated specifically using the WHO/HAI standard survey 89 method(10).

90 Safety indicators

Safety indicators are included in the evaluation criteria, the amount of information related to adverse reaction reporting and adverse reaction events is low, in the process of adverse drug reaction reporting, the reporting rate of new serious adverse drug reactions is high, while the reporting rate of common and minor adverse reactions is low, the data collected through the adverse reaction reporting platform is very little, in order to improve the evaluation of drug safety, information on patient safety was analyzed and the incidence of common adverse reactions in practice with the three 98 ophthalmic anti-VEGF drugs was analyzed on the basis of whether the use of 99 Aflibercept, Conbercept and Leizumab was followed by the use of drugs to combat the 100 symptoms of related adverse reactions. Adverse effects of elevated IOP as a test for 101 common adverse effects because this adverse effect is not susceptible to the patient's 102 own illness and disease progression. If other indicators need to be evaluated the data 103 can be mined in depth.

104

Effectiveness indicators

105 By analyzing the number of days between two ophthalmic anti-VEGF drug 106 injections in patients, the longer interval is considered to be a case where the drug has 107 a strong therapeutic effect on the disease and thus the effectiveness of that ophthalmic 108 anti-VEGF drug. The number of drug changes and the number of cases changed were 109 counted, and the data were finally enumerated based on the discharge dates of patients 110 in the real world data to obtain the hospitalization intervals, as the reasons for drug 111 changes may be influenced by many aspects such as the physician's personal medication 112 habits, drug availability and the actual situation during treatment. To ensure a more 113 accurate evaluation of the effectiveness of each of the three ophthalmic anti-VEGF 114 drugs, patients who had been hospitalised more than twice but had changed ophthalmic 115 anti-VEGF drugs were excluded from the effectiveness evaluation, and only patients 116 who had been hospitalised twice or more and had not changed ophthalmic anti-VEGF 117 drugs were included in the evaluation of effectiveness indicators.

119 **Economic indicators**

The economy of Aflibercept, Conbercept and Leizumab was evaluated by statistically analyzing the cost of the patient's hospitalisation and the total hospitalisation cost to assess whether there was a significant difference between the three ophthalmic anti-VEGF drugs. Patients' surgical costs were analyzed against the costs of Aflibercept, Conbercept and Leizumab to evaluate whether there was a significant difference.

126

6 Appropriateness indicators

127 The appropriateness of these three ophthalmic anti-vascular drugs was assessed 128 based on indications in real-world data for Aflibercept, Conbercept and Leizumab and 129 information on drug indications in the drug formulary. When doctors use the anti-VEGF 130 drugs clinically, they diagnose the patient, default the diagnosis stated by the doctor to 131 be correct, analyze whether the indications for Aflibercept, Conbercept and Leizumab 132 comply with the drug indication when used in the real world based on the diagnosis, 133and the number of cases meeting the drug indications was also compared with the 134 number of cases using the three drugs mentioned above and a chi-square analysis was 135used to derive the difference in suitability between Aflibercept, Conbercept and 136 Leizumab.

137 Accessibility indicators

138 The accessibility of the three ophthalmic anti-VEGF drugs was evaluated based 139 on real world data characteristics. The evaluation was carried out using the per capita

140 income assessment burden of disease method. The accessibility of the three ophthalmic 141 anti-VEGF drugs was evaluated by analyzing the total cost of the drug spent on a 142 standard dose of the drug to treat a disease over a course of treatment, which was 143 equivalent to a multiple of daily disposable income per capita. The multiples of 144 Aflibercept, Conbercept and Leizumab equivalent to urban and rural per capita 145 disposable income were calculated based on the data of urban and rural disposable 146 income in the Henan Provincial Statistical Yearbook 2021 published by the Statistical 147 Bureau of Henan Province, China and the cost per course of treatment of Aflibercept, 148 Conbercept and Leizumab in real world data.

149 Indicators of innovativeness

Review the relevant literature to obtain the time on the market and the respective patent status of Aflibercept, Conbercept and Leizumab to evaluate the innovativeness of the above three ophthalmic anti neovascular drugs. The evaluation was based on the number of patents.

154 **Statistics**

Different statistical analysis methods were adopted according to the characteristics
of the data, including one-way ANOVA and multivariate descriptive statistics.

157

159 **Results**

160 **Patient characteristics**

According to the inclusion criteria of this study, a total of 1292 patients at the First Affiliated Hospital of Zhengzhou University had used at least one of the three drugs, Aflibercept, Conbercept and Leizumab, between January 2020 and December 2020, of which 200 patients used Aflibercept, 311 patients used Conbercept, 665 patients used Leizumab, 112 patients used one of 1 and then switched to the other, and 4 patients used all 3 ophthalmic anti-VEGF drugs.

167 **Safety**

168 There were a certain number of cases in the real-world data in which Aflibercept, Conbercept and Leizumab were followed by three IOP-lowering drugs, brimonidine, 169 170brinzolamide/timolol and brinzolamide, to control the symptoms of elevated IOP 171following intravitreal injection of ophthalmic anti-VEGF drugs. The number of cases 172in which the IOP-lowering drugs brimonidine, brinzolamide \ timolol and brinzolamide 173were used after injections of Aflibercept, Conbercept and Leizumab was: 49 out of 200 174cases in which the IOP-lowering drugs were used in patients who had been given 175Aflibercept (Fig 1). Of the 311 patients who had used Conbercept, a total of 81 patients 176 used of IOP-lowering medication (Fig 2). Of the 665 patients who used Leizumab, a 177total of 148 patients used an IOP-lowering drug (Fig 3).

178

180 Figure 1 The use of three IOP-lowering drugs after the use of Aflibercept



183 Figure 2 The use of three IOP-lowering drugs after the use of Conbercept



189 Figure 3 The use of three IOP-lowering drugs after the use of Leizumab



190

191 Effectiveness

Cases that used only one of Aflibercept, Conbercept and Leizumab and were hospitalised twice or more were analyzed according to the basic characteristics of all cases included in the study and the mean number of days in hospital for such cases was calculated. Calculations showed that the mean number of days between hospitalisations was 56.6 days for patients on Aflibercept, 49.3 days for those on Conbercept and 59.6 days for those on Leizumab.

198 **Economics**

After analyzing the cost and total cost of the three ophthalmic anti-VEGF drugs and the cost of surgery in patients using anti-VEGF drugs for ocular injections, the statistical results were that there was no statistical difference between Aflibercept and Conbercept (p>0.05), Aflibercept and Leizumab (p>0.05) and There was no statistical difference in cost between Conbercept and Leizumab (p>0.05) Table 1.

204

Table 1	Comparison of the cost of three anti-VEGF drugs with the total cost of
hospitalisa	tion
LSD	

202					
Dependent Variable	(I)Drug Codes	(J)Drug Codes	Mean Different(I-J)	Std.Error	Sig.
Western medicine fees	^r estern edicine Aflibercept C es		-476.65	282.01223	0.091
		Leizumab	-267.91	250.792	0.286
	Conbercept	Aflibercept	476.65	282.01223	0.091
		Leizumab	208.74	213.35447	0.328
	Leizumab	Aflibercept	267.91	250.792	0.286
		Conbercept	-208.74	213.35447	0.328
Total cost	Aflibercept	Conbercept	-3576.96*	882.97479	0
		Leizumab	-1738.99*	776.68559	0.025
	Conbercept	Aflibercept	3576.96*	882.97479	0
		Leizumab	1837.97*	725.61256	0.011
	Leizumab	Aflibercept	1738.99*	776.68559	0.025
		Conbercept	-1837.97*	725.61256	0.011

*. The level of significance of the difference in means is 0.05.

206 In terms of the total cost of the three ophthalmic anti-VEGF drugs, there was a 207 statistical difference between the total cost of Aflibercept and Conbercept (p<0.05), the 208 total cost of Aflibercept and Leizumab (p<0.05) and the total cost of Conbercept and 209 Leizumab (p<0.05). The statistical results between the surgical costs of the three 210 ophthalmic anti-VEGF drugs were statistically different between the surgical costs of 211 Aflibercept and Conbercept (p < 0.05) Table 2. There was no statistical difference between the cost of surgery for Aflibercept and Leizumab (p > 0.05). There was a 212 213 statistically significant difference between the cost of surgery for Conbercept and 214 Leizumab (p < 0.05). The significance level of the difference in means was 0.05.

			Mean				
Dependent			Difference				
Variable			(I-J)	Std. Error	Sig.		
Operation	Aflibercept	Conbercept	-922.35*	229.58148	0.000		
Fee		Leizumab	-69.22	204.16561	0.735		
	Conbercept	Aflibercept	922.35*	229.58148	0.000		
		Leizumab	853.12*	173.68834	0.000		
	Leizumab	Aflibercept	69.22	204.16561	0.735		
		Conbercept	-853.12*	173.68834	0.000		
Medicine	Aflibercept	Conbercept	-476.65	282.01223	0.091		
costs		Leizumab	-267.91	250.79200	0.286		
	Conbercept	Aflibercept	476.65	282.01223	0.091		
		Leizumab	208.74	213.35447	0.328		
	Leizumab	Aflibercept	267.91	250.79200	0.286		
		Conbercept	-208.74	213.35447	0.328		

Table 2	Comparison of the cost of three anti-VEGF drugs with the cost of
surgery	

*. The mean difference is significant at the 0.05 level.

215 Appropriateness

LSD

216 Classify the patient's disease according to the primary diagnosis in the real world 217 versus other diagnoses, code and record the classified diagnoses. The indications for 218 Aflibercept, Conbercept, and Leizumab were analyzed for real-world application in 219 accordance with the drug specification. Aflibercept intraocular injection is indicated for 220 the treatment of neovascular (wet) age-related macular degeneration (nAMD) in adults; 221 diabetic macular oedema (DME). Conbercept is indicated for the treatment of: 222 neovascular (wet) age-related macular degeneration (nAMD); visual impairment due to 223 choroidal neovascularisation (pmCNV) secondary to pathological myopia; visual 224 impairment secondary to diabetic macular oedema (DME). Leizumab is used for the 225 treatment of wet (neovascular) age-related macular degeneration (AMD), visual

226	impairment due to diabetic macular oedema (DME), visual impairment due to macular
227	oedema secondary to retinal vein occlusion (RVO) (branch retinal vein occlusion
228	(BRVO) or central retinal vein occlusion (CRVO)), choroidal neovascularisation (CNV,
229	i.e secondary to pathological myopia (PM) and other causes of CNV). After comparing
230	the real-world indications for the three ophthalmic anti-VEGF drugs with those in the
231	medication aid, statistical analysis showed that of the 200 patients who used Aflibercept,
232	138 had a primary diagnosis that matched the drug's instructions and 62 had a primary
233	diagnosis that differed from the drug's instructions Table 3.

Table 3Comparison of compliance with the indications for Afliberceptand Conbercept

Title		Aflibercept	Conbercept	χ2	р
Is it qualified	yes	138	171	10.004	0.002
	no	62	140		
Total		200	311		

A. 0 cells (0.0%) are expected to have counts less than 5. The minimum expected count is 79.06.

234	Of the 311	patients who	used Conberce	pt, 171 pa	tients had a	primary	diagnosis
-----	------------	--------------	---------------	------------	--------------	---------	-----------

that was in accordance with the drug instructions and 140 patients had a primary

236 diagnosis that was different from the drug instructions Table 4.

and Leizumab					
Title		Aflibercept	Leizumab	χ2	р
Is it qualified	yes	138	409	3.717	0.054
	no	62	256		
Total		200	665		

Table 4Comparison of compliance with the indications for Afliberceptand Leizumab

A. 0 cells (0.0%) are expected to have counts less than 5. The minimum expected count is 73.53.

238 Of the 665 patients who used Leizumab, 409 patients had a primary diagnosis that

239 was consistent with the drug insert and 256 patients had a primary diagnosis that was

240 different from the drug insert Table 5.

Table 5Comparison of compliance with the indications for Conberceptand Leizumab

Title		Conbercept	Leizumab	χ2	р
Is it qualified	yes	171	409	3.736	0.053
	no	140	256		
Total		311	665		

A. 0 cells (0.0%) are expected to have counts less than 5. The minimum expected count is 126.18.

There was a statistically significant difference (p<0.05) between Aflibercept and Conbercept in complying with the indications. There was no statistical difference (p>0.05) between Aflibercept and Leizumab in terms of indication compliance, and no statistical difference (p>0.05) between Conbercept and Leizumab in terms of indication compliance.

248 Accessibility

249 Calculate the cost per course of treatment for Abciximab, Conbercept and 250 Leizumab as a multiple of the per capita disposable income of urban and rural residents. 251For urban residents, the multiplier of per capita urban disposable income per course of 252 treatment is 0.229 for Abciximab, 0.226 for Conbercept and 0.218 for Leizumab. For 253 rural residents, a multiple of 1.068 per course of Abciximab, 1.053 per course of 254 Conbercept and 1.014 per course of Leizumab is equivalent to the rural per capita 255 disposable income. The World Health Organization considers a course of medication 256 less than 1 times daily income as good affordability(11) Table 6.

anordaonity			
Drug	Formulation	Urban	Rural
Aflibercept	Injection	0.229	1.068
Conbercept	Injection	0.226	1.053
Leizumab	Injection	0.218	1.014

Table6	Urban/rural per	capita daily	disposable	income	evaluation
affordabil	itv				

257 Innovativeness

258	Aflibercept was appre	oved for marketin	g by the FDA	in 2011, and was	launched in
	1 11		0)	,	

259 China in 2018. Conbercept was launched in China in 2013. Leizumab was approved for

260 marketing by the FDA in 2006 and launched in China in 2018. The number of patents

for Aflibercept is 33, 40, 33 for 2018-2020. the number of patents for Conbercept is 2,

262 3, 0. the number of patents for Leizumab is 24, 7, 25 respectively Table 7.

Table 7Number of patents for three ophthalmic anti-VEGF drugs2018-2020

	Aflibercept	Conbercept	Leizumab	
2018	33	0	25	
2019	40	3	7	
2020	33	2	24	
Total	106	5	56	

263

264 **Discussion and conclusion**

In this study, a multidimensional, systematic and scientific comprehensive evaluation of three ophthalmic anti-VEGF drugs was carried out, evaluating the three drugs in terms of safety, efficacy, economy, innovation, appropriateness and accessibility, with reference to the comprehensive clinical evaluation of the drugs. The study was conducted around the characteristics of comprehensiveness, with reliable sources of research data and more credible results. The results of the comprehensive

evaluation of medicines conducted in this study can provide a reference for the clinical
use process. The comprehensive evaluation of drugs emphasizes the comprehensive
nature of the evaluation, including the evaluation content, evaluation methods and
evaluation results.

The comprehensive evaluation of this study showed that, in terms of safety evaluation, all three ophthalmic anti-VEGF drugs experienced adverse effects of elevated IOP, which improved with the treatment of three different IOP-lowering drugs. The cause of IOP elevation during intravitreal injection of anti-VEGF drugs does not exclude the situation due to surgical manipulation, therefore it is important to examine the affected eye before administering IOP-lowering drugs and before proceeding with the next symptomatic treatment.

In terms of efficacy evaluation, the short dosing interval of Conbercept is relatively weak according to the efficacy evaluation criteria. Aflibercept has a longer dosing interval and is more effective. Leizumab has a long dosing interval and is highly effective. Based on the number of cases of the three ocular anti-VEGF drugs used in our hospital in 2020, the number of cases using Leizumab was the highest, which may be related to physicians' dosing habits and the early availability of Leizumab.

In terms of economic evaluation, there was no significant difference in the cost of Aflibercept, Conbercept and Leizumab, and there was a significant difference in the total cost of all three. Analysis of the cost of surgery for all three revealed a significant difference between Aflibercept and Conbercept and a significant difference between

292 Conbercept and Leizumab. The difference in surgical costs suggests that the frequency 293 of neovascular drug treatment varies between patients depending on the diagnosis of 294 the disease and the degree of disease progression. As there is no price level difference 295 between Aflibercept, Conbercept and Leizumab in the overall treatment process, the 296 other dimensions of the drug can be prioritized when choosing anti-VEGF drugs for the 297 treatment of ophthalmic disease.

298 In terms of appropriateness assessment, Aflibercept is more suitable compared to 299 Conbercept, there is no significant difference between Aflibercept and Leizumab, and 300 there is no significant difference between Conbercept and Leizumab. When there are 301 many off-label use cases of a drug in the real world, the research on the indication of 302 the drug needs to be further strengthened. At the same time, clarification of the cause 303 of the disease and the correct choice of ophthalmic anti-VEGF drugs during treatment 304 will ensure optimal efficacy of the drug. It is important to avoid the irrational use and 305 abuse of ophthalmic anti-VEGF drugs.

In terms of accessibility evaluation, the affordability of Aflibercept, Conbercept and Leizumab appears significantly different for urban and rural residents. For the urban population, Aflibercept, Conbercept and Leizumab were all affordable. The affordability of Leizumab is the strongest. Aflibercept is relatively the least affordable. Aflibercept, Conbercept and Leizumab cannot be afforded to rural residents. Ranibizumab was relatively less burdensome, and aflibercept was the most difficult to bear. According to the per capita disposable income of urban residents, three

- 313 ophthalmic anti-VEGF drugs can be affordable, while the cost of three ophthalmic anti-
- 314 VEGF drugs for rural residents will be unaffordable.
- 315 In terms of innovation evaluation, the patent value of Leizumab is medium,
- 316 inferior to that of Aflibercept and superior to that of Conbercept.
- 317 A thorough understanding of the characteristics of the three drugs will help in the
- 318 selection of clinical use.
- 319

320 Acknowledgements

We thank Yu-shen Li and Yang Yang for their informational support. No potential
 conflict of interest was reported by the author(s).

323

324

325 **References**

- 326 1. Wong WL, Su XY, Li X, Cheung CMG, Klein R, Cheng CY, et al. Global
- 327 prevalence of age-related macular degeneration and disease burden projection for
- 328 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health.
- 329 **2014;2(2):E106-E16**.
- 330 2. Khadka J, McAlinden C, Pesudovs K. Validation of the National Eye Institute Visual
- 331 Function Questionnaire-25 (NEI VFQ-25) in Age-Related Macular Degeneration.
- 332 Invest Ophthalmol Vis Sci. 2012;53(3):1276-.

333	3. Song P, Du Y, Chan KY, Theodoratou E, Rudan I. The national and subnational
334	prevalence and burden of age-related macular degeneration in China. Journal of
335	Global Health. 2017;7(2).
336	4. Low A, Faridi A, Bhavsar KV, Cockerham GC, Freeman M, Fu R, et al. Comparative
337	effectiveness and harms of intravitreal antivascular endothelial growth factor agents
338	for three retinal conditions: a systematic review and meta-analysis. Br J Ophthalmol.
339	2019;103(4):442-51.
340	5. Cheung N, Wong IY, Wong TY. Ocular Anti-VEGF Therapy for Diabetic
341	Retinopathy: Overview of Clinical Efficacy and Evolving Applications. Diabetes

- 342 Care. 2014;37(4):900-5.
- 343 6. Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD, et al.
- 344 Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration.

345 Ophthalmology. 2012;119(12):2537-48.

- 346 7. Schmidt-Erfurth U, Chong V, Loewenstein A, Larsen M, Souied E, Schlingemann
- 347 R, et al. Guidelines for the management of neovascular age-related macular
- 348 degeneration by the European Society of Retina Specialists (EURETINA). Br J
- 349 Ophthalmol. 2014;98(9):1144-67.
- 350 8. Lu XM, Sun XD. Profile of conbercept in the treatment of neovascular age-related
- 351 macular degeneration. Drug Des Dev Ther. 2015;9:10.
- 352 9. Pieramici DJ, Avery RL. Ranibizumab: treatment in patients with neovascular age-
- related macular degeneration. Expert Opin Biol Th. 2006;6(11):1237-45.

354	10. World Health O, Health Action I. Measuring medicine prices, availability,
355	affordability and price components. 2nd edition ed. Geneva: World Health
356	Organization; 2008.
357	11. Mendis S, Fukino K, Cameron A, Laing R, Filipe A, Jr., Khatib O, et al. The
358	availability and affordability of selected essential medicines for chronic diseases in
359	six low- and middle-income countries. Bull World Health Organ. 2007;85(4):279-
360	88.
361	



Figure 1 The use of three IOP-lowering drugs after the use of Aflibercept







Figure 3 The use of three IOP-lowering drugs after the use of Leizumab